Elicio Therapeutics company info

What does Elicio Therapeutics do?
Elicio Therapeutics (NASDAQ:ELTX) is dedicated to advancing vaccine and immunotherapy technologies for treating cancer and other serious diseases. Operating from its base, Elicio focuses on developing a robust pipeline of products aimed at eliciting potent immune responses targeted specifically at disease sites. Their projects integrate cutting-edge research in amphiphile technology to design therapies that precisely activate the immune system, promising a new era of precision medicine. Elicio's objectives are centered on transforming the landscape of cancer treatment, making therapies more effective and accessible to patients globally. Through continuous innovation and strategic collaboration, Elicio strives to achieve breakthroughs that will redefine standards of care in immuno-oncology.
Elicio Therapeutics company media
Company Snapshot

Is Elicio Therapeutics a public or private company?


How many people does Elicio Therapeutics employ?


What sector is Elicio Therapeutics in?

pie chart
Health Care

Where is the head office for Elicio Therapeutics?

location pin
Head Office
Boston, United States

What year was Elicio Therapeutics founded?

founded flag
Year Founded
What does Elicio Therapeutics specialise in?
/Immunotherapy Development /Cancer Treatment /ELI-002 Product /Lymph Node Targeting /Amphiphile Platform /Vaccine Enhancements

What are the products and/or services of Elicio Therapeutics?

Overview of Elicio Therapeutics offerings
Immunotherapy Research & Development: Elicio focuses on researching and developing ELI-002, a vaccine targeting mKRAS mutations in cancer, and potentially other similar therapies in the future.
Clinical Trial Management: Elicio conducts and manages clinical trials to test the safety and efficacy of their drug candidates like ELI-002.
Collaboration with Research Institutions: Elicio might collaborate with research institutions for further development of their therapies or technologies.
Data Analysis & Reporting: They analyze data from clinical trials and report the findings to regulatory agencies and the scientific community.
Investor Relations & Communication: Elicio communicates with investors regarding their progress and developments.
Technology Development: They work on developing and improving their Elicio AMP Technology platform for creating new immunotherapies.

Who is in the executive team of Elicio Therapeutics?

Elicio Therapeutics leadership team
  • Mr. Robert T. Connelly
    Mr. Robert T. Connelly
    CEO, President & Director
  • Dr. Christopher M. Haqq M.D., Ph.D.
    Dr. Christopher M. Haqq M.D., Ph.D.
    Executive VP, Head of Research & Development and Chief Medical Officer
  • Prof. Darrell J. Irvine Ph.D.
    Prof. Darrell J. Irvine Ph.D.
    Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board
  • Mr. Brian  Piekos
    Mr. Brian Piekos
    Chief Financial Officer
  • Mr. Michael  DiVecchia
    Mr. Michael DiVecchia
    Senior Vice President of Operations & Human Resources
  • Dr. Peter  DeMuth Ph.D.
    Dr. Peter DeMuth Ph.D.
    Chief Scientific Officer
  • Ms. Megan C. Filoon
    Ms. Megan C. Filoon
    General Counsel, Secretary & Compliance Officer
  • Ms. Esther  Welkowsky
    Ms. Esther Welkowsky
    Senior Vice President of Clinical Development